Related Experiment Videos
Dysphoric mania. Clinical and biological correlates.
R M Post1, D R Rubinow, T W Uhde
1Biological Psychiatry Branch, National Institute of Mental Health, Bethesda, MD 20892.
Archives of General Psychiatry
|April 1, 1989
Summary
Dysphoric mania, characterized by depression and anxiety, is linked to more hospitalizations and distinct biological markers. This severe manic subtype may respond better to carbamazepine than lithium.
Area of Science:
- Psychiatry and Neuroscience
- Mood Disorders Research
Background:
- Manic episodes can present with significant depressive symptoms (dysphoria) and anxiety.
- Dysphoric mania is recognized as a subtype with potentially poorer prognoses.
Purpose of the Study:
- To investigate the clinical, biological, and pharmacological characteristics of dysphoric mania.
- To compare dysphoric manic patients with nondysphoric manic patients.
- To explore potential treatment responses in this patient subgroup.
Main Methods:
- Studied patients at peak manic episode severity.
- Compared dysphoric (n=22) and nondysphoric (n=26) manic patients.
- Analyzed cerebrospinal fluid norepinephrine concentrations in medication-free patients (n=22).
Main Results:
- Dysphoric manics had more prior hospitalizations and less rapid cycling than nondysphoric manics.
- Manic dysphoria severity correlated with hospitalization history, especially in women.
- Medication-free dysphoric manics showed elevated cerebrospinal fluid norepinephrine, correlating with dysphoria, anger, and anxiety.
Conclusions:
- Dysphoric mania exhibits distinct clinical and biological features, including higher hospitalization rates and elevated norepinephrine.
- This subtype may have differential responses to mood stabilizers, potentially favoring carbamazepine over lithium.
- Further research into dysphoric mania subgroups is warranted due to clinical significance.